KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) FCF Margin (2017 - 2025)

Aquestive Therapeutics has reported FCF Margin over the past 9 years, most recently at 61.81% for Q4 2025.

  • Quarterly results put FCF Margin at 61.81% for Q4 2025, down 768.0% from a year ago — trailing twelve months through Dec 2025 was 117.82% (down 5556.0% YoY), and the annual figure for FY2025 was 117.82%, down 5556.0%.
  • FCF Margin for Q4 2025 was 61.81% at Aquestive Therapeutics, up from 100.6% in the prior quarter.
  • Over the last five years, FCF Margin for AQST hit a ceiling of 79.16% in Q1 2023 and a floor of 269.9% in Q1 2025.
  • Median FCF Margin over the past 5 years was 73.21% (2021), compared with a mean of 67.48%.
  • Biggest five-year swings in FCF Margin: skyrocketed 192430bps in 2021 and later tumbled -18350bps in 2025.
  • Aquestive Therapeutics' FCF Margin stood at 77.58% in 2021, then skyrocketed by 201bps to 78.54% in 2022, then plummeted by -148bps to 37.54% in 2023, then plummeted by -44bps to 54.12% in 2024, then decreased by -14bps to 61.81% in 2025.
  • The last three reported values for FCF Margin were 61.81% (Q4 2025), 100.6% (Q3 2025), and 80.19% (Q2 2025) per Business Quant data.